MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/19458924221109987

Медицинская библиотека · American journal of rhinology & allergy · 2022

Clinical and Quality of Life Outcomes Following Temperature-Controlled Radiofrequency Neurolysis of the Posterior Nasal Nerve (RhinAer) for Treatment of Chronic Rhinitis.

Lee Jivianne T, Abbas Gregory M, Charous Daniel D, Cuevas Pd Dr Med Mandy, Göktas Prof Dr Med Önder, Loftus Patricia A, Nachlas Nathan E, Toskala Elina M, Watkins Jeremy P, Brehmer Prof Dr Med Detlef

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Temperature-controlled radiofrequency (TCRF) neurolysis of the posterior nasal nerve (PNN; RhinAer) is a minimally invasive treatment option for patients with chronic rhinitis.

OBJECTIVE

To determine clinical outcomes and quality of life (QoL) following TCRF neurolysis of the PNN.

METHODS

A prospective single-arm study of 129 patients with chronic rhinitis at 16 medical centers in the United States and Germany.

RESULTS

The mean 24-h reflective total nasal symptom score (rTNSS) improved from 7.8 (95% CI, 7.5-8.1) at baseline to 3.6 (95% CI, 3.2-4.0) at 3 months and continued to improve to 2.9 (95% CI, 2.5-3.3) at 6 months (p < .001 comparing follow-up to baseline and p = .002 comparing 3 and 6 months). This represents 53.8% improvement over baseline at 3 months and 62.8% improvement at 6 months. Rhinorrhea, congestion, sneezing, and itching subscores and postnasal drip and cough scores were all significantly improved over baseline at both timepoints. At 3 months, 76.2% (95% CI, 68.1%-82.8%) of patients achieved a minimal clinically important difference of ≥30% improvement in rTNSS over baseline and the percentage was higher at 6 months (83.5% [95% CI, 75.8%-89.0%]). At 3 months, 80.3% (95% CI, 72.6%-86.3%) reported a minimal clinically important difference of ≥0.4-point improvement in the mini rhinoconjunctivitis quality of life questionnaire score, and the percentage was higher at 6 months; 87.7% (95% CI, 80.7%-92.4%). There were no serious adverse events with a relationship to the device/procedure reported through 6 months.

CONCLUSION

In this large, multicenter study, TCRF neurolysis of the PNN was safe and resulted in a significant reduction in rhinitis symptom burden at 3 months that was sustained/improved through 6 months. The majority of patients reported a clinically relevant improvement in QoL at 3 and 6 months postprocedure.

Для цитирования: Lee Jivianne T, Abbas Gregory M, Charous Daniel D, Cuevas Pd Dr Med Mandy, Göktas Prof Dr Med Önder, Loftus Patricia A, Nachlas Nathan E, Toskala Elina M, Watkins Jeremy P, Brehmer Prof Dr Med Detlef. Clinical and Quality of Life Outcomes Following Temperature-Controlled Radiofrequency Neurolysis of the Posterior Nasal Nerve (RhinAer) for Treatment of Chronic Rhinitis.. American journal of rhinology & allergy. 2022. DOI: 10.1177/19458924221109987.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.